u/slow_logbook_notes

Push back: your plan is an employer plan, which changes both the appeal path and who the regulator is.

the Medsafe position in New Zealand is its own thing entirely

Read the published criteria for my indication rather than asking.

Agreed — the database rather than the coverage, every time.

Correction: that is the registration decision, not the subsidy listing. They are made by different bodies.

The escalation schedule in the trials existed to keep people on the drug. It is a tolerability ramp, and it is why the label reads the way it does.

STEP-1 ran 68 weeks and landed just under 15% mean body weight change on 2.4mg. It is an average of a wide distribution, not a target you have missed.

Is this a prior authorisation denial or a formulary exclusion?

Yes — four nations, four pathways, and threads that ignore that give people the wrong answer confidently.

Four pharmacies, four prices, same product, same month. The spread was larger than I expected and none of them were the headline offer.

What did the referral letter actually say?

Adding the practical bit — ask what happens at discharge before you start, not after.

Switched pharmacies mid-titration and had to restart the ladder because the concentrations did not line up.

Added a jurisdiction tag — the answers differ completely between countries and plan types.

Adding the underused one — external review. Independent, binding where it applies, and hardly anybody gets that far.

That figure is a private price at one pharmacy, not a national one.

I would not skip the peer-to-peer. It is often the fastest route and it costs a phone call.

Yes. Week 58 is when almost everybody writes the "is it still working" post, and almost everybody is fine.

Agreed on the plan-year point. Criteria that applied last year may simply not apply now.

Step therapy requires documented trial of preferred alternatives. It is not an argument to be won on merits; it is a record to be produced, and the record is what the appeal must contain.

Same view. The second-level appeal is where mine turned, after a first-level denial that looked final.

private prescription pricing moves monthly and the pharmacy is most of the spread

a peer-to-peer call is often faster than a written appeal

Minor fix — the half-life is about a week, not about a day. The rest of your point stands.

Sat at 1.7mg for four months because it was doing the job. Everyone told me to go up. The one time I did, the only thing that changed was the fatigue.

nausea that arrives on day two and fades by day four is the standard shape